Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-01-12Clinical Trial Update: A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens [Phase 2]
Phase 2 study evaluating subcutaneous daratumumab in combination with standard multiple myeloma regimens; results were posted after completi…
-
CLINICAL_TRIALS trial_result · 2022-01-11Clinical Trial Update: Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma [Phase 1]
Phase 1 clinical trial evaluating Letetresgene Autoleucel alone and with pembrolizumab in NY-ESO-1 positive multiple myeloma; the study is t…
-
CLINICAL_TRIALS trial_result · 2022-01-10Clinical Trial Update: Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma [Phase 3]
Phase 3 trial evaluating safety of pomalidomide plus low-dose dexamethasone in relapsed/refractory multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2022-01-10Clinical Trial Update: Quality Assurance of Secondary Immunodeficiencies (SID) in CLL/MM Patients
A completed clinical trial evaluating quality assurance of secondary immunodeficiencies in patients with chronic lymphocytic leukemia or mul…
-
CLINICAL_TRIALS trial_result · 2021-12-21Clinical Trial Update: Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma [Phase 1, Phase 2]
Clinical trial updates the combination of ibrutinib with carfilzomib in relapsed/refractory multiple myeloma; status completed with results …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2021-12-17EMA Authorised: Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka) (lenalidomide hydrochloride monohydrate) — Krka, d.d., Novo mesto
EMA authorised lenalidomide Krka d.d. Novo mesto for indications including multiple myeloma and follicular lymphoma, establishing its market…
-
CLINICAL_TRIALS trial_result · 2021-12-09Clinical Trial Update: B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial evaluating B cell maturation antigen (BCMA) targeted CAR-T cells for relapsed/refractory multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2021-12-02Clinical Trial Update: Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions [Phase 2]
Phase 2 clinical trial evaluating a busulfan/melphalan/fludarabine conditioning regimen with T-cell depleted allogeneic hematopoietic stem c…
-
CLINICAL_TRIALS trial_result · 2021-12-01Clinical Trial Update: sdAb-based TRNT of Multiple Myeloma: a Feasibility Study [NA]
Feasibility study of sdAb-based TRNT for multiple myeloma completed; results posted in 2021.
-
FDA approval · 2021-11-30FDA Approved: DARZALEX FASPRO — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for DARZALEX FASPRO submitted by Janssen Biotech, Inc. to modify/expand its labeling or indication.
-
CLINICAL_TRIALS trial_result · 2021-11-24Clinical Trial Update: Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma [Phase 2]
Phase 2 clinical trial update for an intervention targeting symptom burden during maintenance therapy in multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2021-11-23Clinical Trial Update: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1) [Phase 1, Phase 2]
Phase 1/2 study evaluating a fully human BCMA-targeting CAR T therapy (CT103A) in relapsed/refractory multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2021-11-09Clinical Trial Update: Autologous Transplant for Multiple Myeloma [Phase 2, Phase 3]
A completed phase 2/3 trial evaluating autologous transplant for multiple myeloma with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-11-09Clinical Trial Update: Isatuximab in Type I Cryoglobulinemia [Phase 2]
Phase 2 trial update for isatuximab in cryoglobulinemic vasculitis associated with monoclonal gammopathies isatuximab is being studied; curr…
-
FDA approval · 2021-11-04FDA Approved: VELCADE — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for Velcade (bortezomib) submitted by Takeda Pharmaceuticals America, Inc. This approval covers …
-
CLINICAL_TRIALS trial_result · 2021-10-28Clinical Trial Update: A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2a study of MOR202 (anti-CD38) in relapsed/refractory multiple myeloma has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2021-10-27Clinical Trial Update: A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma [Phase 2]
Phase 2 study of ixazomib with dexamethasone in adults with relapsed and/or refractory multiple myeloma completed; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-10-27Clinical Trial Update: S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 trial evaluating S1211 consisting of bortezomib, dexamethasone, and lenalidomide with or without elotuzumab for newly diagnosed …
-
CLINICAL_TRIALS trial_result · 2021-10-25Clinical Trial Update: Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients [Phase 3]
Phase 3 trial evaluating BiRd regimen with BCMA CAR T-cell therapy in newly diagnosed multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2021-10-18Clinical Trial Update: MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation [Phase 3]
Phase 3 trial studying Velcade (bortezomib) for multiple myeloma patients after autologous transplantation; terminated with results posted.
-
FDA approval · 2021-10-14FDA Approved: LENALIDOMIDE — Original Application (Dr. Reddy's Laboratories Inc.)
The FDA approved Dr. Reddy's Laboratories' original application for lenalidomide (generic), authorizing a generic version of the cancer drug…
-
CLINICAL_TRIALS trial_result · 2021-10-07Clinical Trial Update: A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 1]
Phase 1 study in subjects with relapsed or refractory multiple myeloma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-09-30Clinical Trial Update: Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies [Phase 1, Phase 2]
Clinical trial update on combining acalabrutinib (ACP-196) with ACP-319 for B-cell malignancies, including non-Hodgkin lymphoma, multiple my…
-
CLINICAL_TRIALS trial_result · 2021-09-23Clinical Trial Update: Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma [Phase 2]
Phase II study of IRD (ixazomib, lenalidomide, dexamethasone) after autologous stem cell transplantation in multiple myeloma, followed by ma…
-
CLINICAL_TRIALS trial_result · 2021-09-16Clinical Trial Update: Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 study evaluating ixazomib with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma has completed with posted re…